

**International CardiOncology Society
(ICOS)
&
Cardiac Safety Research Consortium
(CSRC):
How Are We Aligned?**

Joseph R. Carver, FACC

5 October 2011

Deaths and death rates for the 10 leading causes of death in specified age groups: United States, preliminary 2009

Data based on a continuous file of records received from the states. Rates are per 100,000 population in specified group.
Cause of death based on the *International Classification of Diseases Tenth Revision, 2004*

| Rank | | Number | Rate |
|----------|---|------------------|--------------|
| | All ages | | |
| | All causes | 2,436,652 | 793.7 |
| 1 | Diseases of heart | 598,607 | 195.0 |
| 2 | Malignant neoplasms | 568,668 | 185.2 |
| 3 | Chronic lower respiratory diseases | 137,082 | 44.7 |

Kochanek KD, Xu JQ, Murphy SL, et al. Deaths: Preliminary data for 2009.
National vital statistics reports; vol 59 no 4.
Hyattsville, MD: National Center for Health Statistics. 2011.

Cardiovascular toxicity of chemotherapeutic agents

Drugs associated with CHF

**Anthracyclines/anthraquinolones
Cyclophosphamide
Trastuzumab and other monoclonal antibody-based tyrosine kinase inhibitors**

Drugs associated with ischaemia or thromboembolism

**Antimetabolites (fluorouracil, capecitabine)
Antimicrotubule agents (paclitaxel, docetaxel)
Cisplatin
Thalidomide**

Drugs associated with hypertension

**Bevacizumab
Cisplatin
Sunitinib, sorafenib**

Drugs associated with other toxic effects

Tamponade and endomyocardial fibrosis

Busulfan

Haemorrhagic myocarditis (rare)

Cyclophosphamide (high-dose therapy)

Bradyarrhythmias

Paclitaxel

Raynaud's phenomenon

Vinblastine, bleomycin

Autonomic neuropathy

Vincristine

Intersecting Interests: CSRC & ICOS

- **Cardiac safety in treatment**
 - Identify high-risk drugs and high-risk patients
- **Improve diagnostic screening and monitoring predictive power**
 - Imaging and biomarkers
- **Toxicity assessment, grading and reporting**
 - Universal definitions and nomenclature

Intersecting Interests: CSRC & ICOS

- **Guideline development**
- **New drug development**
 - A “seat at the table”
- **Education**
 - Professional and public

Future Collaborations

- **Research**
- **Guideline development**
- **Data base development**
- **Joint role in new product development**
- **Joint Board seats**

How Are We Aligned?

Our goals and key objectives are so similar that ICOS could easily be renamed:

**International CardiOncology Safety
Research Consortium**